CompoAtlas

B-Complex Powder

En venta en el mercado estadounidense (según DSLD)

Catie's, complemento alimenticio del mercado estadounidense

B-Complex Powder (Catie's), complemento alimenticio au code-barres 850015534126, se describe mediante su etiqueta del mercado estadounidense. Si se vendiera en Francia, le afectarían 3 puntos de la normativa francesa o europea, detallados a continuación. La fórmula vendida en Europa con el mismo nombre puede ser diferente.

Etiqueta oficial. Dietary Supplement Label Database (DSLD), Institutos Nacionales de la Salud de Estados Unidos (NIH): etiquetas a la venta o retiradas del mercado, consultado el 27 de octubre de 2026.

Fuente: NIH, Office of Dietary Supplements, Dietary Supplement Label Database (CC0); etiquetas del mercado estadounidense.

Si este producto se vendiera en Francia

Solo se calcula una dosis diaria si la etiqueta indica el número máximo de tomas y una unidad de masa (o unidades internacionales para la vitamina D). Las cantidades proceden de la etiqueta, no de un análisis. En Estados Unidos, la etiqueta presenta este producto como «dietary supplement»; en Francia, un producto de este tipo puede pertenecer a otra categoría (por ejemplo, un polvo para deportistas) y las dosis máximas de los complementos alimenticios no serían aplicables.

Composición de la etiqueta

Marca
Catie's
Código de barras
850015534126
Forma
Polvo
Una toma
3,8 g
Tomas
número de tomas diarias no indicado
Ingrediente (tal como aparece, en inglés)CategoríaPor toma
B-Complex Proprietary BlendMezcla2.706 mg
Alfalfa (Medicago sativa)Plantano indicada
Apricot, Powder (Prunus armeniaca)Plantano indicada
Spearmint (Mentha spicata)Plantano indicada
Sea BuckthornPlantano indicada
Holy BasilPlantano indicada
Nettle (Urtica dioica)Plantano indicada
Moringa (Moringa oleifera)Plantano indicada
AsparagusPlantano indicada
Watercress, PowderPlantano indicada
Sunflower LecithinLípidono indicada
Licorice, PowderPlantano indicada
Shitake Mushroom (Lentinula edodes)Plantano indicada
SpinachPlantano indicada
Lemon, Powder (Citrus limon)Plantano indicada
Coriander, Powder (Coriandrum sativum)Plantano indicada
MagnoliaPlantano indicada
ChickpeaPlantano indicada
Cayenne (Capsicum annuum)Plantano indicada
Fenugreek (Trigonella foenum-graecum)Plantano indicada
Royal JellyIngrediente de origen animalno indicada
Cornsilk (Zea mays)Plantano indicada
Bee PollenIngrediente de origen animalno indicada
CarrotPlantano indicada
Yellow DockPlantano indicada
Witch Hazel (Hamamelis virginiana)Plantano indicada

Etiqueta mostrada: Etiqueta oficial. Se priorizan las etiquetas a la venta y, después, la más reciente para un mismo estado.

Esta información recoge la etiqueta estadounidense registrada por los Institutos Nacionales de la Salud de Estados Unidos (NIH). No indica si el producto es eficaz ni sustituye el consejo de un médico o farmacéutico, especialmente durante el embarazo o un tratamiento.

Advertencias oficiales (Health Canada)

Health Canada publica advertencias sobre estos ingredientes:

  • Alfalfa
    Leer la advertencia, cuándo se aplica y los estudios citados

    Texto original oficial en inglés.

    ALFALFA - MEDICAGO SATIVA

    Vía de administración: Oral

    Precauciones y advertencias

    Se aplica a los productos: providing more than 900 mg of Alfalfa dried herb top/leaf, per day.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners, birth control medication or hormone therapy (Brinker 2010; Barnes et al. 2007; Boon and Smith 2004).

    Fuentes citadas por Health Canada (3)
    • Barnes J, Anderson LA, Philipson JD. Herbal Medicines, 3rd edition. London (UK): Pharmaceutical Press; 2007.
    • Boon H, Smith MJ. The Complete Natural Medicine Guide to the 50 Most Common Medicinal Herbs, 2nd edition. Toronto (ON): Robert Rose Inc; 2004.
    • Brinker F. Herb Contraindications and Drug Interactions, 4e édition. Sandy (OR): Eclectic Medical Publications; 2010.

    Contraindicaciones

    Condición de aplicación: All products.

    Do not use if you are pregnant or breastfeeding (Brinker 2010; Barnes et al. 2007; Boon and Smith 2004).

    Fuentes citadas por Health Canada (3)
    • Barnes J, Anderson LA, Philipson JD. Herbal Medicines, 3rd edition. London (UK): Pharmaceutical Press; 2007.
    • Boon H, Smith MJ. The Complete Natural Medicine Guide to the 50 Most Common Medicinal Herbs, 2nd edition. Toronto (ON): Robert Rose Inc; 2004.
    • Brinker F. Herb Contraindications and Drug Interactions, 4e édition. Sandy (OR): Eclectic Medical Publications; 2010.

    Se aplica a los productos: providing more than 900 mg of Alfalfa dried herb top/leaf, per day.

    Do not use if you have a history of systemic lupus erythematosus (Brinker 2010; Barnes et al. 2007; Boon and Smith 2004).

    Fuentes citadas por Health Canada (3)
    • Barnes J, Anderson LA, Philipson JD. Herbal Medicines, 3rd edition. London (UK): Pharmaceutical Press; 2007.
    • Boon H, Smith MJ. The Complete Natural Medicine Guide to the 50 Most Common Medicinal Herbs, 2nd edition. Toronto (ON): Robert Rose Inc; 2004.
    • Brinker F. Herb Contraindications and Drug Interactions, 4e édition. Sandy (OR): Eclectic Medical Publications; 2010.

    Monografía de Health Canada del 29 de noviembre de 2024

  • Nettle
    Leer la advertencia, cuándo se aplica y los estudios citados

    Texto original oficial en inglés.

    STINGING NETTLE JUICE

    Vía de administración: Oral

    Precauciones y advertencias

    Condición de aplicación: All products except nutritive tonics.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Contraindicaciones

    Do not use if you are pregnant or breastfeeding (Brinker 2010; Barnes et al. 2007; Tilgner 1999).

    Fuentes citadas por Health Canada (3)
    • Barnes J, Anderson LA, Philipson JD. Herbal Medicines, 3rd edition. London (UK): The Pharmaceutical Press; 2007.
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Tilgner S. Herbal Medicine from the Heart of the Earth. Creswell (OR): Wise Acre Press; 1999.

    Reacciones adversas conocidas

    Condición de aplicación: All products except those making only a diuretic claim*.

    When using this product diuretic effect may occur.

    *Note: This statement can be removed from the label if a diuretic claim is included.

    Monografía de Health Canada del 27 de marzo de 2026

    STINGING NETTLE - URTICA DIOICA

    Vía de administración: Oral

    Precauciones y advertencias

    Condición de aplicación: All products except nutritive tonics.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Contraindicaciones

    Do not use if you are pregnant or breastfeeding (Brinker 2010; Barnes et al. 2007; Tilgner 1999).

    Fuentes citadas por Health Canada (3)
    • Barnes J, Anderson LA, Philipson JD. Herbal Medicines, 3rd edition. London (UK): The Pharmaceutical Press; 2007.
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Tilgner S. Herbal Medicine from the Heart of the Earth. Creswell (OR): Wise Acre Press; 1999.

    Reacciones adversas conocidas

    All products except those making only a diuretic claim*

    When using this product diuretic effect may occur.

    *Note: This statement can be removed from the label if a diuretic claim is included.

    Monografía de Health Canada del 27 de marzo de 2026

  • Cayenne
    Leer la advertencia, cuándo se aplica y los estudios citados

    Texto original oficial en inglés.

    CAYENNE - CAPSICUM ANNUUM Oral

    Precauciones y advertencias

    Condición de aplicación: All products.

    Keep out of the reach of children. If overdose or accidental ingestion occurs, call a poison control centre or get medical help right away (CPS 2008).

    Fuentes citadas por Health Canada (1)
    • CPS 2008: Repchinksy C, Welbanks L, Bhalla A, Fortin K, Jarvis B, Jovaisas B, Acharya S. Compendium of Pharmaceutical Specialties. Ottawa (ON): Canadian Pharmacists Association; 2008.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Bradley 2006; Boon and Smith 2004).

    Fuentes citadas por Health Canada (2)
    • Boon H, Smith MJ. The Complete Natural Medicine Guide to the 50 Most Common Medicinal Herbs, 2nd edition. Toronto (ON): Robert Rose Inc; 2004.
    • Bradley PR, editor. British Herbal Compendium: A Handbook of Scientific Information on Widely Used Plant Drugs, Volume 2. Bournemouth (GB): British Herbal Medicine Association; 2006.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have stomach ulcers or inflammation (Brinker 2010).

    Fuentes citadas por Health Canada (1)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.

    Condición de aplicación: Digestion; Peripheral circulation.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Monografía de Health Canada del 27 de marzo de 2026

    CAYENNE - CAPSICUM ANNUUM/CAPSAICIN Topical

    Precauciones y advertencias

    Condición de aplicación: All products.

    For external use only (US FDA 2023).

    Fuentes citadas por Health Canada (1)
    • US FDA 2023: United States Food and Drug Administration. Over-the-Counter Monograph M017: External Analgesics Drug Products for Over-the-Counter Human Use. Washington (DC): U.S. Food and Drug Administration, Department of Health and Human Services. [Accessed 2026 February 27]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/omuf/monographs/OTC%20Monograph_M017-External%20Analgesic%20Drug%20Products%20for%20OTC%20Human%20Use%2005.02.2023.pdf

    1 estudio citado en el texto no tiene referencia correspondiente en la monografía (véanse las anomalías en la página de fuentes).

    When using this product avoid contact with the eyes and mucous membranes. If contact occurs, rinse thoroughly with water (US FDA 2023).

    Fuentes citadas por Health Canada (1)
    • US FDA 2023: United States Food and Drug Administration. Over-the-Counter Monograph M017: External Analgesics Drug Products for Over-the-Counter Human Use. Washington (DC): U.S. Food and Drug Administration, Department of Health and Human Services. [Accessed 2026 February 27]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/omuf/monographs/OTC%20Monograph_M017-External%20Analgesic%20Drug%20Products%20for%20OTC%20Human%20Use%2005.02.2023.pdf

    1 estudio citado en el texto no tiene referencia correspondiente en la monografía (véanse las anomalías en la página de fuentes).

    Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist, worsen, or re-occur within a few days (US FDA 2023).

    Fuentes citadas por Health Canada (1)
    • US FDA 2023: United States Food and Drug Administration. Over-the-Counter Monograph M017: External Analgesics Drug Products for Over-the-Counter Human Use. Washington (DC): U.S. Food and Drug Administration, Department of Health and Human Services. [Accessed 2026 February 27]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/omuf/monographs/OTC%20Monograph_M017-External%20Analgesic%20Drug%20Products%20for%20OTC%20Human%20Use%2005.02.2023.pdf

    1 estudio citado en el texto no tiene referencia correspondiente en la monografía (véanse las anomalías en la página de fuentes).

    Keep out of the reach of children. If swallowed, call a poison control centre or get medical help right away (CPS 2008).

    Fuentes citadas por Health Canada (1)
    • CPS 2008: Repchinksy C, Welbanks L, Bhalla A, Fortin K, Jarvis B, Jovaisas B, Acharya S. Compendium of Pharmaceutical Specialties. Ottawa (ON): Canadian Pharmacists Association; 2008.

    Reacciones adversas conocidas

    Condición de aplicación: All products.

    Stop use if headache, redness, rashes, burning discomfort and/or hypersensitivity occur (Brayfield and Cadart 2024; Zhang et al. 2008; Hoffman 2003; APhA 2002; McCleane 2000).

    Fuentes citadas por Health Canada (5)
    • APhA 2002: Berardi RR, DeSimone EM, Newton GGD, Oszko MA, Popovich NG, Rollins CJ, Shimp LA, Tietze KJ, editors. Handbook of Nonprescription Drugs: An interactive approach to self-care. 13th edition. Washington (DC): American Pharmaceutical Association; 2002.
    • Brayfield A, Cadart C, editors. Martindale: The Complete Drug Reference. London (GB): Pharmaceutical Press; 2024. [Accessed 2024 August 14]. Available from: https://www.medicinescomplete.com/#/browse/martindale
    • Hoffman D. Medical Herbalism: The Science and Practice of Herbal Medicine. Rochester (VT): Healing Arts Press; 2003.
    • McCleane G. Topical application of doxepin hydrochloride, capsaicin and a combination of both produces analgesia in chronic human neuropathic pain: a randomized, double-blind, placebo-controlled study. British Journal of Clinical Pharmacology 2000;49:574-579. PubMed Ensayo aleatorizado
    • Zhang W, Moskowitz, RW, Nuki G, Abramson S, Altman RD, Arden N, Bierma-Zeinstra S, Brandt KD, Croft P, Doherty M, Dougados M, Hochberg M, Hunter DJ, Kwoh K, Lohmander LS, Tugwell P. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis and Cartilage 2008;16:137-162. PubMed Revisión sistemática

    Monografía de Health Canada del 27 de marzo de 2026

  • Fenugreek
    Leer la advertencia, cuándo se aplica y los estudios citados

    Texto original oficial en inglés.

    FENUGREEK - TRIGONELLA FOENUM-GRAECUM - Oral

    Precauciones y advertencias

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant (Gardner and McGuffin 2013; Brinker 2010; Mills et al. 2006; Hoffman 2003; Blumenthal et al. 2000).

    Fuentes citadas por Health Canada (4)
    • Blumenthal M, Goldberg A, Brinkmann J, editors. Herbal Medicine: Expanded Commission E Monographs. Boston (MA): Integrative Medicine Communications; 2000.
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Gardner Z, McGuffin M, editors. American Herbal Products Association's Botanical Safety Handbook. 2nd edition. Boca Ration (FL): Taylor and Francis Group; 2013.
    • Mills E, Duguoa J, Perri D, Koren G. Herbal Medicines in Pregnancy and Lactation. An Evidence-Based Approach. New York (NY): Taylor and Francis; 2006.

    1 estudio citado en el texto no tiene referencia correspondiente en la monografía (véanse las anomalías en la página de fuentes).

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have diabetes (Brinker 2010; Mills and Bone 2005).

    Fuentes citadas por Health Canada (2)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Mills S, Bone K. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone; 2005.

    Monografía de Health Canada del 29 de mayo de 2026

    FENUGREEK - TRIGONELLA FOENUM-GRAECUM - Topical

    Precauciones y advertencias

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Monografía de Health Canada del 29 de mayo de 2026

  • Royal Jelly
    Leer la advertencia, cuándo se aplica y los estudios citados

    Texto original oficial en inglés.

    ROYAL JELLY

    Vía de administración: Oral

    Precauciones y advertencias

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.

    Contraindicaciones

    Do not use if you have a history of asthma or allergies (TGA 2001; Leung et al. 1997; Harwood et al. 1996; Laporte et al. 1996; Thien et al. 1996; Leung et al. 1995; Peacock et al. 1995; Bullock 1994).

    Fuentes citadas por Health Canada (8)
    • Bullock RJ. Fatal royal-jelly induced asthma. Medical Journal of Australia 1994;160:44. PubMed Caso clínico
    • Harwood M, Harding S, Beasley R, Frankish PD. Asthma following royal jelly. The New Zealand Medical Journal 1996;109:325. PubMed Caso clínico
    • Laporte JR, Ibaanez L, Vendrell L, Ballarin E. Bronchospasm induced by royal jelly. Allergy 1996;51:440. PubMed
    • Leung R, Ho A, Chan J, Choy D, Lai CK. Royal jelly consumption and hypersensitivity in the community. Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology 1997;27(3):333-336. PubMed
    • Leung R, Thien FC, Baldo B. Royal Jelly-induced asthma and anaphylaxis: clinical characteristics and immunologic correlations. Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology 1995;96:1004-1007. PubMed Caso clínico
    • Peacock S, Muray V, Turton C. Respiratory distress and royal jelly. British Medical Journal 1995;311:1472. PubMed Caso clínico
    • TGA 2001: Australian Therapeutic Goods Administration. CMEC 28: Complementary Medicines Evaluation Committee, Extracted Ratified Minutes twenty-eight Meeting, 27-28 July 2001. Australian Government Department of Health and Aging, Sydney, Australia; 2001. [Accessed 2025 February 5]. Available from: https://www.tga.gov.au/sites/default/files/cmec-minutes-28.pdf
    • Thien FC, Leung R, Baldo BA, Weiner JA, Plomley R, Czarny D. Asthma and anaphylaxis induced by royal jelly. Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology 1996;26(2):216-222. PubMed

    Reacciones adversas conocidas

    Stop use if hypersensitivity/allergy occurs (Leung et al. 1997; Laporte et al. 1996; Thien et al. 1996; Leung et al. 1995; Peacock et al. 1995).

    Fuentes citadas por Health Canada (6)
    • Laporte JR, Ibaanez L, Vendrell L, Ballarin E. Bronchospasm induced by royal jelly. Allergy 1996;51:440. PubMed
    • Leung R, Ho A, Chan J, Choy D, Lai CK. Royal jelly consumption and hypersensitivity in the community. Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology 1997;27(3):333-336. PubMed
    • Leung R, Thien FC, Baldo B. Royal Jelly-induced asthma and anaphylaxis: clinical characteristics and immunologic correlations. Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology 1995;96:1004-1007. PubMed Caso clínico
    • Peacock S, Muray V, Turton C. Respiratory distress and royal jelly. British Medical Journal 1995;311:1472. PubMed Caso clínico
    • Thien FC, Leung R, Baldo BA, Weiner JA, Plomley R, Czarny D. Asthma and anaphylaxis induced by royal jelly. Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology 1996;26(2):216-222. PubMed
    • Harwood M, Harding S, Beasley R, Frankish PD. Asthma following royal jelly. The New Zealand Medical Journal 1996;109:325. PubMed Caso clínico

    Monografía de Health Canada del 24 de abril de 2026

  • Witch Hazel
    Leer la advertencia, cuándo se aplica y los estudios citados

    Texto original oficial en inglés.

    WITCH HAZEL - HAMAMELIS VIRGINIANA Buccal and Oromucosal

    Vía de administración: Buccal Oromucosal

    Precauciones y advertencias

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Monografía de Health Canada del 27 de febrero de 2026

    WITCH HAZEL - HAMAMELIS VIRGINIANA Ophthalmic

    Precauciones y advertencias

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms worsen or persist (for) more than 2 days (EMA 2009).

    Fuentes citadas por Health Canada (1)
    • EMA 2009: European Medicines Agency. Committee on Herbal Medicinal Products. Community Herbal Monograph on Hamamelis virginiana L., folium et cortex aut ramunculus destillatium. [Accessed 2026 February 3]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-hamamelis-virginiana-l-folium-cortex-aut-ramunculus-destillatum_en.pdf

    Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if you experience eye pain, changes in vision, continued redness, or irritation of the eye (EMA 2009).

    Fuentes citadas por Health Canada (1)
    • EMA 2009: European Medicines Agency. Committee on Herbal Medicinal Products. Community Herbal Monograph on Hamamelis virginiana L., folium et cortex aut ramunculus destillatium. [Accessed 2026 February 3]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-hamamelis-virginiana-l-folium-cortex-aut-ramunculus-destillatum_en.pdf

    Monografía de Health Canada del 27 de febrero de 2026

    WITCH HAZEL -HAMAMELIS VIRGINIANA Oral

    Precauciones y advertencias

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Barnes et al. 2007; ESCOP 2003).

    Fuentes citadas por Health Canada (2)
    • Barnes J, Anderson LA, Philipson JD. 2007. Herbal Medicines, 3rd edition. London (GB): The Pharmaceutical Press.
    • ESCOP 2003: European Scientific Cooperative on Phytotherapy Scientific Committee. 2003. ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy and Thieme.

    Reacciones adversas conocidas

    When using this product you may experience gastrointestinal discomfort/disturbances (Gardner and McGuffin 2013; ESCOP 2003; Berardi et al. 2002; Mills and Bone 2000).

    Fuentes citadas por Health Canada (4)
    • Berardi RR, DeSimone EM, Newton GD, Oszko MA, Popovich NG, Rollins CJ, Shimp LA, Tietze KJ, editors. 2002. Handbook of Nonprescription Drugs: An Interactive Approach to Self-Care, 13th edition. Washington (DC): American Pharmaceutical Association.
    • ESCOP 2003: European Scientific Cooperative on Phytotherapy Scientific Committee. 2003. ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy and Thieme.
    • Gardner Z, McGuffin M, editors. American Herbal Products Association's Botanical Safety Handbook. Second Edition. Boca Raton (FL): Taylor and Francis Group; 2013.
    • Mills S, Bone K. 2000. Principles and Practice of Phytotherapy. Toronto (ON): Churchill Livingstone.

    Monografía de Health Canada del 27 de febrero de 2026

    WITCH HAZEL - HAMAMELIS VIRGINIANA Topical

    Precauciones y advertencias

    Condición de aplicación: All products.

    For external use only.

    When using this product avoid contact with eyes. If contact occurs, rinse thoroughly with water.

    Keep out of reach of children. If swallowed, call a poison control centre or get medical help right away.

    Se aplica a los productos: for use on minor wounds/burns/bruises/irritations/inflammations or on hemorrhoids.

    Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms worsen, last (for) more than 7 days.

    Se aplica a los productos: for use on varicose veins.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Contraindicaciones

    Se aplica a los productos: for use on minor wounds/burns/bruises/irritations/inflammations.

    Do not use on deep or puncture wounds, animal bites or serious burns.

    Reacciones adversas conocidas

    Condición de aplicación: All products.

    Stop use if a skin rash occurs (ESCOP 2003; Berardi et al. 2002; Mills and Bone 2000).

    Fuentes citadas por Health Canada (3)
    • Berardi RR, DeSimone EM, Newton GD, Oszko MA, Popovich NG, Rollins CJ, Shimp LA, Tietze KJ, editors. Handbook of Nonprescription Drugs: An Interactive Approach to Self-Care, 13th edition. Washington (DC): American Pharmaceutical Association; 2002.
    • ESCOP 2003: European Scientific Cooperative on Phytotherapy Scientific Committee. ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy and Thieme; 2003.
    • Mills S, Bone K. Principles and Practice of Phytotherapy. Toronto (ON): Churchill Livingstone; 2000.

    Se aplica a los productos: for use on hemorrhoids.

    Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if you experience bleeding.

    Monografía de Health Canada del 27 de febrero de 2026

Se refieren al ingrediente, no a este producto ni a su dosis. No sustituyen el consejo médico.

Lista declarada el (registro: Dietary Supplement Label Database (DSLD), Institutos Nacionales de la Salud de Estados Unidos (NIH): etiquetas a la venta o retiradas del mercado).

Fotografiar el envase

Marca : Catie's

¿Alguna información inexacta o más reciente sobre este producto, sea usted lector o marca? Escriba a contact@compoatlas.com: cada corrección se publica en el registro de correcciones.

Lista registrada en 2023. Fotografíe el envase para comprobar si ha cambiado.

Intro para analizar, Mayús+Intro para una nueva línea